BLAINJECTIONSOLUTIONPriority Review
Approved
Dec 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
4/8 — Partial
Priority Review
ELZONRIS (tagraxofusp) by Stemline Therapeutics is cd123 interactions [moa]. First approved in 2018.
Drug data last refreshed 6h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELZONRIS (tagraxofusp-erzs) is a CD123-targeted recombinant immunotoxin approved in December 2018 for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic malignancy. It works by binding to CD123 on malignant cells and delivering a diphtheria toxin payload to induce cell death. This mechanism represents a novel targeted approach to treating this previously difficult-to-treat disease.
Peak
Product is in peak commercial stage with 30% competitive pressure; team size likely stable with focused oncology specialization.
Mechanism of Action
CD123 Interactions
Pharmacologic Class:
CD123 Interaction
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Started Feb 2026
31 enrolled
Acute Myeloid Leukaemia (AML)LeukemiaBlood Cancer+1 more
Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients
Started Dec 2025
33 enrolled
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Started Feb 2025
20 enrolled
Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
Started Jan 2025
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Started Jan 2025
85 enrolled
Acute Myeloid Leukemia
Worked on ELZONRIS at Stemline Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.